Welcome to our dedicated page for ZEO ScientifiX SEC filings (Ticker: ZEOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ZEO ScientifiX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ZEO ScientifiX's regulatory disclosures and financial reporting.
ZEO ScientifiX, Inc. filed a report describing a humanitarian initiative supported by the company. Medical Advisory Board member Dr. Constantino Mendieta joined a 10-day pediatric burn reconstruction mission in Cusco, Peru, where he used products that had been donated to him by ZEO ScientifiX.
During the mission, approximately 80 children were evaluated and nearly 40 reconstructive surgeries were performed over six days at the Regional Hospital of Cusco. ZEO frames this product donation as part of a broader commitment to physician-led care, regenerative medicine education, and expanding access to advanced therapeutic options for patients in need.
Zeo ScientifiX, Inc. reported sharply higher sales but remains unprofitable and faces substantial doubt about its ability to continue as a going concern. Revenue for the three months ended April 30, 2026 rose to $2.58 million from $1.15 million, driven mainly by allogenic biologic products in Florida’s evolving stem cell market. Six‑month revenue reached $4.03 million, with gross margins around 80%.
The company still posted a net loss of $145,000 for the quarter and $997,000 for the six months, though losses narrowed versus the prior year. Operating cash outflow was $609,000 over six months, offset by $1.95 million of equity financing and $376,000 from selling its Exotropin stake, lifting cash to $1.85 million. At April 30, 2026, stockholders’ equity improved to $712,000 and working capital to $155,000, yet management and auditors still highlight regulatory risk around FDA stem‑cell rules, reliance on new state laws such as Florida SB 1768, and the need for additional funding to support clinical trials and growth.
Zeo ScientifiX, Inc. reported stock option awards to a major holder and related entity. The filing shows grants of options under the company’s 2021 Equity Incentive Plan, exercisable at an exercise price of $1.67 per share and expiring on June 10, 2036.
Footnotes explain that the options were issued to Greyt Ventures, LLC, a principal stockholder and consultant owned by a trust for which Wendy Grey is trustee. One grant vests upon achieving performance milestones, while another vested in full at the grant date, and both are exercisable on a cashless basis with anti-dilutive features tied to large future issuances.
Zeo ScientifiX, Inc. reported that CEO, CFO and 10% owner Ian T. Bothwell received two grants of stock options on June 10, 2026. Each grant covers 625,000 options to buy common stock at an exercise price of $1.67 per share.
The first grant vested in full on the grant date and is exercisable on a cashless basis for ten years under the company’s 2021 Equity Incentive Plan. The second grant also covers 625,000 options, vests upon achievement of specified performance milestones, is exercisable cashless for up to ten years, and is described as antidilutive for future transactions issuing 10% or more of fully diluted common shares. These are compensation-related awards, not open‑market share purchases.
Zeo ScientifiX, Inc. reported that Chief Medical Officer George Craig Shapiro received two stock option awards. Each grant covers 625,000 options on common stock at an exercise price of $1.67 per share, dated June 10, 2026.
One grant vests in full as of the grant date and is exercisable on a cashless basis for ten years under the 2021 Equity Incentive Plan. The other vests upon specified performance milestones and is also exercisable cashless for ten years once vested, and is described as antidilutive for future transactions issuing at least 10% of common stock on a fully diluted basis.
Zeo ScientifiX, Inc. director Bretz Charles Luther received a grant of stock options to buy 80,000 shares of common stock. The options have an exercise price of $1.67 per share, were fully vested on the June 10, 2026 grant date, and expire on June 10, 2031. Following this award, he holds stock options covering 80,000 underlying shares as direct derivative holdings, reflecting equity-based compensation rather than an open-market trade.
Zeo ScientifiX, Inc. reported new stock option awards under its 2021 Incentive Stock Plan. On June 10, 2026, the company granted options for 625,000 shares of common stock each to Greyt Ventures LLC, CEO/CFO and director Ian Bothwell, and Chief Medical Officer and director George Shapiro. These options are fully vested, exercisable on a cashless basis for ten years, with an exercise price of $1.67 per share.
The company also granted 625,000 additional “Incentive Options” to each of Greyt Ventures LLC, Bothwell, and Shapiro that vest upon achievement of specified performance milestones and are exercisable on a cashless basis for ten years at $1.67 per share. These Incentive Options are described as antidilutive for any future transaction that issues 10% or more of common stock on a fully diluted basis. In addition, Zeo ScientifiX awarded options for 80,000 shares to non-executive director Chuck Bretz, fully vested at grant, exercisable for five years at $1.67 per share.
ZEO ScientifiX, Inc. expanded its Medical Advisory Board by adding nine physicians and scientific innovators across disciplines such as orthopedics, oncology, longevity science, pain management, plastic surgery, and advanced biologic therapies. The board is positioned as a core scientific body focused on research, clinical protocols, and high clinical standards rather than marketing endorsements.
The advisors will guide scientific development, regenerative biologics, and physician education, including programs like the Physician-Led Patient Masterclass and initiatives connected to the $101 million XPRIZE Healthspan longevity prize competition, where the company is a semi-finalist. ZEO ScientifiX describes itself as a clinical-stage biopharmaceutical company focused on regenerative biologics and physician education.
ZEO ScientifiX, Inc. filed a current report describing the launch of its new Physician-Led Patient Masterclass program in regenerative medicine. The program is designed to help doctors educate current and potential patients on the science, appropriate use cases, and safety considerations of regenerative therapies.
ZEO notes it has trained more than 600 physicians across the Southeast in the past year on clinical applications of regenerative therapies, including stem cell use for pain management, wound care, and orthopedics under Florida law. The new Masterclass formalizes a physician-hosted, locally tailored patient education model that the company now plans to roll out across its Florida physician network.
Zeo Scientifix, Inc. insider Ian T. Bothwell filed Amendment No. 3 to his Schedule 13D, reporting beneficial ownership of 1,195,094 shares of common stock, or 14.7% of the class based on 7,777,441 shares outstanding as of March 16, 2026.
This total includes common shares, warrants and options held by Bothwell. He also holds 50 shares of Series C Preferred Stock that provide an additional 25.5% of the company’s total voting power, giving him combined voting power of 40.2%. Recent changes reflect equity awards under the company’s 2021 Equity Incentive Plan.